Degnim Amy C, Ghosh Karthik, Vierkant Robert A, Winham Stacey J, Hoskin Tanya L, Carter Jodi M, McCauley Bryan M, Jensen Matt R, Allers Teresa, Frost Marlene, Gehling Denice L, Fischer Jessica L, Seymour Lisa R, Pacheco-Spann Laura M, Rosenberg Philip S, Denison Lori A, Vachon Celine M, Hartmann Lynn C, Radisky Derek C, Sherman Mark E
Division of Breast and Melanoma Surgical Oncology, Mayo Clinic, Rochester, MN 55905, United States.
General Internal Medicine, Mayo Clinic, Rochester, MN 55905, United States.
JNCI Cancer Spectr. 2025 Jan 3;9(1). doi: 10.1093/jncics/pkae128.
Benign breast disease (BBD) increases breast cancer (BC) risk progressively for women diagnosed with nonproliferative change, proliferative disease without atypia (PDWA), and atypical hyperplasia (AH). Leveraging data from 18 704 women in the Mayo BBD Cohort (1967-2013), we evaluated temporal trends in BBD diagnoses and how they have influenced associated BC risk over 4 decades.
BC risk trends associated with BBD were evaluated using standardized incidence ratios (SIRs) and age-period-cohort modeling across 4 eras-premammogram (1967-1981), precore needle biopsy (CNB) (1982-1992), transition to CNB (1993-2001), and CNB era (2002-2013).
With a median follow-up of 15.8 years, 9.9% of women were diagnosed with BC (invasive and/or DCIS). From the premammogram era to the CNB era, we observed a significant increase in BC risk, rising from an SIR of 1.61 to 1.99. The proportion of proliferative BBD diagnoses (PDWA or AH) increased markedly over time (28.1%-49.7%), as did the proportion of DCIS events (11%-28%; χ2 P < .001). Within specific BBD categories, the risk of invasive BC increased modestly.
Absolute risk of BC within BBD categories remained stable, but the relative risk of BC after BBD increased over time due to notable increases in higher risk BBD lesions, specifically PDWA and AH. These findings illustrate how evolving screening practices have changed the risk profile of BBD and should inform management strategies for patients with BBD in modern clinical settings.
对于诊断为非增殖性改变、无异型增生的增殖性疾病(PDWA)和非典型增生(AH)的女性,良性乳腺疾病(BBD)会逐渐增加患乳腺癌(BC)的风险。利用梅奥BBD队列(1967 - 2013年)中18704名女性的数据,我们评估了BBD诊断的时间趋势以及它们在40年中如何影响相关的BC风险。
使用标准化发病率比(SIRs)和年龄 - 时期 - 队列模型,在四个时期评估与BBD相关的BC风险趋势,这四个时期分别为:乳房X线摄影术前(1967 - 1981年)、粗针穿刺活检(CNB)术前(1982 - 1992年)、向CNB过渡时期(1993 - 2001年)和CNB时代(2002 - 2013年)。
中位随访时间为15.8年,9.9%的女性被诊断患有BC(浸润性和/或导管原位癌)。从乳房X线摄影术前时代到CNB时代,我们观察到BC风险显著增加,SIR从1.61上升到1.99。增殖性BBD诊断(PDWA或AH)的比例随时间显著增加(28.1% - 49.7%),导管原位癌事件的比例也增加了(11% - 28%;χ2 P <.001)。在特定的BBD类别中,浸润性BC的风险适度增加。
BBD类别中BC的绝对风险保持稳定,但由于高风险BBD病变(特别是PDWA和AH)显著增加,BBD后BC的相对风险随时间增加。这些发现说明了不断发展的筛查实践如何改变了BBD的风险状况,并应为现代临床环境中BBD患者的管理策略提供参考。